Inherited factors for prostate cancer prostate cancer risk have proven difficult to identify. The results of linkage analysis, the workhorse of gene finding methods for Mendelian disorders, have been notoriously difficult to validate. Within the past year, however, two independent studies have demonstrated that a region on 8q24 confers a strong risk of developing sporadic prostate cancer in men of African and European ancestries. 8q24 is the first bona fide genetic risk locus that is responsible for an appreciable fraction of sporadic prostate cancer cases in the general population, particularly, in African-American men. Our hypotheses are that a genetic variant within 8q24 initiates prostate cancer and impacts the clinical features of the disease. The discovery of this novel locus presents the opportunity to gain deeper insight into prostate cancer biology. Although the region has been identified, the causal allele and the gene that it influences remain to be determined. Since 8q is one of the most frequent regions of somatic amplification in prostate cancer, we will also have the opportunity to explore connections between the germline and somatic genomes. Understanding the genetic and molecular pathways driving prostate cancer can ultimately lead to improved diagnostic and therapeutic capabilities. From a clinical perspective, patients can be stratified into carriers and non-carriers of this risk allele to explore its impact on clinical variables, such as presentation and disease outcomes. Our goals are to elucidate the genetic pathogenesis and the clinical impact of the 8q24 variant allele on prostate cancer.
The Specific Aims of this Project are to:
Aim 1 : To identify the causal germline allele through fine mapping of the 8q24 region Aim 2: To characterize inherited variation at 8q24 and somatic molecular associations at 8q24 Aim 3: To determine the effect of the germline 8q24 variant on clinical presentation and outcomes in prostate cancer patients

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-08
Application #
7890598
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2009-07-01
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
8
Fiscal Year
2009
Total Cost
$216,178
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104
Pettersson, Andreas; Gerke, Travis; Penney, Kathryn L et al. (2018) MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:201-207
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Graff, Rebecca E; Ahearn, Thomas U; Pettersson, Andreas et al. (2018) Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:193-200
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :

Showing the most recent 10 out of 261 publications